* Q2 sales +3% and EBITDA +4% vs. ABGSCe * We raise EBITDA by 1-4% and EBIT by 4-8% for '26e-'27e * ...
* Q2 NAV in line with ABGSCe * Key highlights: Safe Life transaction and buybacks * Discount still w...
Redeye provides a research update following the Q2 report recently published by Initiator Pharma.
* Sales SEK 6.5m, EBIT SEK -16m (vs. ABGSCe 11m and -12m) * No machine deliveries in the quarter (in...
Mendus’s Q225 results reflect a period of progress across the pipeline.
Solteq’s Q2 result was below our expectations. Retail & Commerce was decent, while Utilities remaine...
* Sales -39% vs. ABGSCe, EBIT SEK 5m vs. ABGSCe 16m * Weak Q2 due to inventory build-up following st...
Redeye comments on I-Tech’s Q2 figures that missed our expectations, driven by weaker sales.
Redeye comments on Sleep Cycle’s Q2 report, which was broadly in line with expectations.
Redeye notes that InfraCom’s Q2 2025 report was below expectations for sales (-9%) and EBITDA (-12%)...
Redeye updates on Better Collective after Q2 where results were slightly below our forecasts while t...
Redeye updates its estimates following Surgical Science’s Q2 2025 report, which aligned with the com...
Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the cor...
* Minor estimate revisions * On track to reach 1m paying users in '25e * Maintain fair value range o...
Vi gör inga förändringar av våra estimat som redan återspeglar en starkare krona och lägre produktio...
Omsättningen sjönk till 6,6 (10,2) meur, varav PremierGaming stod för 5,8%.
Mendus has reported its Q225 results. During the period, it made continued progress on the lead prog...
Redeye provides a research update following the Q2 report published by OncoZenge earlier today.
Dovre’s Q2 saw even more losses, although financial position still appears decent so long as recent ...
Despite a weaker-than-expected quarter in terms of revenue and profitability, we are raising our sal...
